Randomised treatment of acute pancreatitis with infliximab: protocol for a double-blind, placebo-controlled, multi-centre, adaptive, phase 2 superiority trial (RAPID-I). [PDF]
Lin J +30 more
europepmc +1 more source
In this nationwide study of patients with inflammatory bowel disease, TNF inhibitor use was associated with higher bloodstream infection rates, whereas vedolizumab and ustekinumab was not. Associations differed by pathogen species, and concomitant glucocorticoid use was associated with higher infection rates.
Cæcilie Leding +4 more
wiley +1 more source
Associations Between Anti-TNF Pharmacokinetics, Immunogenicity, and Therapeutic Response in Iraqi Patients with Inflammatory Bowel Disease: A Real-World Therapeutic Drug Monitoring Study. [PDF]
Kanna BA, Azeez SS.
europepmc +1 more source
Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis
Objective: to describe real world experience of switching from originator TNF inhibitor Remicade (infliximab), to the biosimilar Inflectra (infliximab) in severe inflammatory arthritis. Methods: from May 2015 patients receiving Remicade (infliximab) were
Underhill, C. +10 more
core
Advanced IBD therapies appear safe and effective in PSC‐IBD. However remission and response rates appear numerically attenuated compared to IBD‐only populations. Created in BioRender (https://BioRender.com/h9bxgij). ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD)
Amera Elzubeir +6 more
wiley +1 more source
Systemic Treatment and Outcome in Erythrodermic Psoriasis: A Retrospective Multicenter Study
This multicentre real‐world study illustrates the heterogeneity of systemic treatment approaches in erythrodermic psoriasis (EP) in Bavaria, Germany. Adverse events were more frequently observed with conventional therapies, whereas biologic therapies showed favorable outcomes.
Julian Kögel +15 more
wiley +1 more source
Autologous hinge-masked anti-TNFα antibody to mitigate immunogenicity, antigen sink effects, and anti-idiotypic antibody interference. [PDF]
Huang BC +12 more
europepmc +1 more source
Emerging Roles of PSTPIP2 in Autoimmunity: From Mechanism to Therapeutic Implications
PSTPIP2 acts as a key brake on myeloid inflammation by suppressing IL‐1β‐driven signalling, macrophage dysregulation and inflammation‐associated bone remodelling. Its emerging roles in CRMO/CMO, rheumatoid arthritis, SAPHO syndrome and bullous pemphigoid support its potential as a biomarker and therapeutic target.
Erdong Zhang +9 more
wiley +1 more source
Associations of Rheumatoid Arthritis Disease Activity With Frailty Over Five Years of Follow‐up
Objective To evaluate whether rheumatoid arthritis (RA) disease activity is associated with frailty both in cross‐section and longitudinally. Methods Participants within the Veterans Affairs Rheumatoid Arthritis (VARA) registry enrolled from 2003 to 2022 were included.
Courtney N. Loecker +14 more
wiley +1 more source
Real-World Experience of Risankizumab in Refractory Pediatric Inflammatory Bowel Disease. [PDF]
Alsarhan A +4 more
europepmc +1 more source

